EGFR-sparing HER2 kinase inhibitor

approved in met. HER2+ BC incl. w/ brain met.

from optimization of known TKIs

Mol. Cancer Ther., Apr. 1, 2020

Array / Cascadian Tx / Seattle Genetics


Tucatinib is the third approved HER2 kinase inhibitor (after lapatinib and neratinib), but differentiates itself due to its selectivity against the closely related EGFR, which is hypothesized to be a…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: